Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Amino acid or derivative
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 6322
Molecular formula: C6H14N4O2
IUPAC: (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
Source: PC-ARGININE
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Urea-cycle amino acid and nitric-oxide synthesis substrate.
Evidence and critical reading
Reported scientific and empirical uses
Reported muscle and performance · Replacement and nutritional context · Cardiovascular and vascular function
Promoted for blood flow, performance and amino-acid blends; effect depends on disease/exposure.
Human evidence
VINTAGE MI did not improve vascular/ventricular function after infarction; six deaths occurred with arginine and none with placebo, and the study stopped. Do not generalize vascular safety.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
VINTAGE MI did not improve vascular/ventricular function after infarction; six deaths occurred with arginine and none with placebo, and the study stopped. Do not generalize vascular safety.
VINTAGE MI did not improve vascular/ventricular function after infarction; six deaths occurred with arginine and none with placebo, and the study stopped. Do not generalize vascular safety.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial.
3 g · Target amount per administration
- Frequency
- Three times/day
- Duration
- Up to six planned months; trial stopped
- Route
- Oral
- Context
- Post-infarction: mortality signal; critical harm record, not a use proposal.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID16391217 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
The post-infarction signal is clinically material. Plausible additive vasodilation with antihypertensives is not a quantified interaction for each blend.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID16391217 · Randomized controlled trial
After myocardial infarction.
Oral, up to six planned months.
No vascular/ventricular benefit; six versus zero deaths, trial stopped.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 153
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Arginine · 785 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT06991738 · 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid CancerRegistry status: Not yet recruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07871786 · Efficacy of a Sonic Toothbrush and 8% Arginine Toothpaste in Reducing Dentinal HypersensitivityRegistry status: CompletedLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07110532 · pH1N1 Blinded Challenge StudyRegistry status: RecruitingLast update posted: October 16, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-ARGININE
October 16, 2026
- PMID16391217
Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G.
October 16, 2026
- SEARCH-PUBMED-arginine
October 16, 2026